Regenerative therapies Flashcards
what are some future treatments in comabtting myelin debris?
- Anti-Nogo A antibodies increase axon regeneration in rat spinal cord injury (further away they moved from lesion )
what do Anti-Nogo antibodies do in non-human primate SCI?
increase functional recovery and sprouting is seen
( it is currently in phase 2 looking at positive effects of recovery)
Explain NogoA knockout experiments?
knockouts have produced variable amounts of axon regeneration after injury.
- one knockout regenerates vigorously
- one regenerates a bit
- one doesn’t regenerate at all
what does a triple knockout of NogoA, MAG and OMgp show?
no regeneration after injury
what are the main functions of (IN A NORMAL CNS):
- microglia
- astrocytes
- oligodendrocytes
microglia: immune surveillance
astrocytes: neuronal support
oligodendrocytes: continually cycling population
what are the major markers/ molecules produced (IN A NORMAL CNS) by :
- microglia
- astrocytes
- oligodendrocytes
microglia: CR3, MCSF and TGFB1
astrocytes: GFAP, CAMs, NGF, FGFs, CNTF, TGFB1
oligodendrocytes: PDGFaR
what CS-PGs are expressed (IN A NORMAL CNS) by:
- microglia
- astrocytes
- oligodendrocytes
microglia: none known
astrocytes: Brevican, versican, phosphacan
oligodendrocytes: NG2, versican
What happens to glial cells in an injured CNS?
All cells become hyperactive
What does an injured CNS do to microglia?
Increases in markers (CR3, MCSF, TGFB1)
New molecules produced: TNFa, IL-1b, IL-6, B7, MHC-I, CAMs, MCSF-R, integrins
Function: antigen recognition, proliferation, hypertrophy
what does an injured CNS do to astrocytes?
Increases in markers (GFAP, CAMs, NGF, FGFs, CNTF, TGFB1)
New molecules produced: TNFa, IL-1, IL-6, tenascin
Function: Scar formation, hypertrophy
Increases in CS-PGs expressed (Brevican, versican, phosphacan)
what does an injured CNS do to oligodendrocyte precursor cell?
Function: Rapid proliferation, hypertrophy
Increases in expressed CS-PGs (NG2, versican)
Molecules produced: PDGFaR
what is Chondroitinase ABC (cABC) ?
an enzyme that digests glycosaminoglycan side chains of CSPGs
describe how you can combat glial scar with cABC?
- after rodent spinal cord injury and digestion of glucosaminoglycan side chains with cABC
- no CSPG immunoreactivity detected
- fibres regrew around lesion site better than untreated
- cABC showed more fibres going around the lesion area
what is a potential problem of cABC?
regrowth following treatment follows to areas where there is digestion of CSPGs
what current treatment could cABC enhance?
rehabilitation